Tests combination treatments in adults with acute myeloid leukemia after treatment
Tests several leukemia drugs, alone or combined, in patients with residual leukemia cells.
Plain-language title generated from the registry record
Registry title: MRD-positive AML Clinical Study
Key facts
- Where
- Tianjin, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged over 14 with acute myeloid leukemia (not APL) who are in complete remission but still have measurable leftover leukemia cells (MRD-positive).
- Age
- Over 14 years old
- Sex
- Men and women
- Disease stage
- AML (non-M3) by WHO 2016 standards, in morphological complete remission, with MRD-positive status
- Biomarker or test result
- MRD-positive, shown by bone marrow flow cytometry, PCR for NPM1 mutation, PCR for fusion genes (RUNX1-RUNX1T1, CBFB-MYH11, DEK-NUP214), or NGS showing FLT3 mutation
Main reasons for not taking part
- Plans to have a hematopoietic stem cell transplant within 4 weeks
- Diagnosis of APL
- Researchers do not consider the person right for the trial
Read by machine on 9 November 2026.
Where in China
- Blood Diseases HospitalTianjin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Trial code
- NCT07131059
- Record updated
- 10 August 2026
- Original description
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small molecule targeted drugs, demethylation drugs, liposome drugs and the combination of these drugs to form a combination of treatment regimen, the specific treatment regimen will be updated according to the results of this trial and the latest research progress at home and abroad.Read full original descriptionShow less
MRD-positive AML: a Prospective, Single-arm, Multicenter Platform Clinical Study
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the following drugs and protocols: Chemotherapy, small molecule targeted drugs, demethylation drugs, liposome drugs and the combination of these drugs to form a combination of treatment regimen, the specific treatment regimen will be updated according to the results of this trial and the latest research progress at home and abroad.
Inclusion: AML (non-M3) compliant with WHO (2016) standards; In morphological complete remission; Mrd-positive patients: including bone marrow flow cytometry, PCR quantification of NPM1 mutations, PCR quantification of fusion genes (RUNX 1-RUNX1T1, CBFB-MYH11 and DEK-NUP214), or NGS detection of FLT3 mutation positive; Age over 14 years old, male or female. Informed consent must be signed prior to the commencement of all specific study procedures, and for those 14 years of age and older, informed consent must be signed by the patient or an immediate family member. Considering the patient's condition, if the patient's signature is not conducive to the treatment of the condition, the informed consent shall be signed by the legal guardian or the patient's immediate family.
Exclusion: Patients who intend to undergo hematopoietic stem cell transplantation within 4 weeks; The diagnosis is APL; Those who were not considered suitable for inclusion by the researchers.